Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.42 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17388419 | 0.95 | L3MBTL1 (0.45) | L3MBTL1MRGPRX4GLANR3C1NR3C2 | |
| SCHEMBL27667253 | 0.81 | L3MBTL1 (0.46) | L3MBTL1MRGPRX4GLACYP19A1CYP11B1 | |
| SCHEMBL6964908 | 0.81 | GLA (0.50) | L3MBTL1MRGPRX4GLANR3C1NR3C2 | |
| SCHEMBL17103408 | 0.81 | L3MBTL1 (0.35) | L3MBTL1MRGPRX4GLANR3C1NR3C2 | |
| SCHEMBL6109806 | 0.78 | SLC6A2 (0.52) | L3MBTL1MRGPRX4GLANR3C1NR3C2 | |
| SCHEMBL4599725 | 0.78 | GLA (0.50) | L3MBTL1MRGPRX4GLACYP19A1CYP11B1 | |
| SCHEMBL30426333 | 0.78 | GLA (0.50) | L3MBTL1MRGPRX4GLACYP19A1CYP11B1 | |
| SCHEMBL2154019 | 0.77 | GLA (0.53) | MRGPRX4GLACYP19A1CYP11B1CYP11B2 | |
| SCHEMBL2153847 | 0.77 | HRH3 (0.59) | MRGPRX4GLACYP19A1CYP11B1CYP11B2 | |
| SCHEMBL5697547 | 0.77 | DAO (0.46) | L3MBTL1MRGPRX4GLACYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339701-B1 | HETEROARYL ALKYL PIPERAZINE DERIVATIVES AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS INC (US) | 2007-02-14 | — | — | EP | disclosed |
| US-6849632-B2 | Heteroaryl alkyl piperazine derivatives | CV THERAPEUTICS, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040192702-A1 | Heteroaryl alkyl piperazine derivatives | ZABLOCKI JEFF (US) | 2004-09-30 | — | — | US | disclosed |
| US-20040029889-A1 | Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors | CV THERAPEUTICS, INC. | 2004-02-12 | — | — | US | disclosed |
| US-20030216409-A1 | Heteroaryl alkyl piperazine derivatives | CV THERAPEUTICS, INC. | 2003-11-20 | — | — | US | disclosed |
| EP-1339701-A1 | HETEROARYL ALKYL PIPERAZINE DERIVATIVES AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6573264-B1 | Protecting skeletal muscles against damage, treating shock conditions, preserving donor tissue and organs used in transplants, treating cardiovascular diseases | CV THERAPEUTICS, INC. | 2003-06-03 | — | — | US | disclosed |
| WO-2002064576-A1 | HETEROARYL ALKYL PIPERAZINE DERIVATIVES AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029889-A1 | Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors | CPT1B, CPT1A, ALOX15 | L3MBTL1 1322/4885MRGPRX4 4353/4885GLA 3020/4885 |
| US-20040192702-A1 | Heteroaryl alkyl piperazine derivatives | ATP2A1, CPT1B, ATP2A3 | L3MBTL1 1574/4885MRGPRX4 3941/4885GLA 1859/4885 |
| US-20030216409-A1 | Heteroaryl alkyl piperazine derivatives | ATP2A1, CPT1B, ATP2A3 | L3MBTL1 1574/4885MRGPRX4 3941/4885GLA 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.